Abstract
Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.
| Original language | English (US) |
|---|---|
| Journal | American Journal of Clinical Nutrition |
| Volume | 54 |
| Issue number | SUPPL. 6 |
| State | Published - Dec 1991 |
| Externally published | Yes |
Fingerprint
Keywords
- Ascorbic acid
- Chemotherapy
- Immunotherapy
- Interleukin-2
- Lymphokine-activated killer cells
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Food Science
Cite this
Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. / Marcus, Stuart L.; Petrylak, Daniel P.; Dutcher, Janice P.; Paietta, Elisabeth M.; Ciobanu, Niculae; Strauman, Janice; Wiernik, Peter H.; Hutner, Seymour H.; Frank, Oscar; Baker, Herman.
In: American Journal of Clinical Nutrition, Vol. 54, No. SUPPL. 6, 12.1991.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells
AU - Marcus, Stuart L.
AU - Petrylak, Daniel P.
AU - Dutcher, Janice P.
AU - Paietta, Elisabeth M.
AU - Ciobanu, Niculae
AU - Strauman, Janice
AU - Wiernik, Peter H.
AU - Hutner, Seymour H.
AU - Frank, Oscar
AU - Baker, Herman
PY - 1991/12
Y1 - 1991/12
N2 - Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.
AB - Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.
KW - Ascorbic acid
KW - Chemotherapy
KW - Immunotherapy
KW - Interleukin-2
KW - Lymphokine-activated killer cells
UR - http://www.scopus.com/inward/record.url?scp=0025885659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025885659&partnerID=8YFLogxK
M3 - Article
C2 - 1962585
AN - SCOPUS:0025885659
VL - 54
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - SUPPL. 6
ER -